Label-free quantification for discovering novel biomarkers in the diagnosis and assessment of disease activity in inflammatory bowel disease

Journal of Digestive Diseases

Volumn 14, Issue 4, 2013, Pages 166-174

  Han, Na Young ^a   Choi, Wooseok ^a   Park, Jong Moon ^a   Kim, Eun Hee ^a,b   Lee, Hookeun ^a   Hahm, Ki Baik ^a,b,c  

^a Gachon University   (South Korea)

^b CHA University   (South Korea)

^c CHA Bundang Medical Center   (South Korea)

Author keywords

Biomarker; Inflammatory bowel disease; Label free quantification; Proteome

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COLON BIOPSY; COLON MUCOSA; COLON POLYP; CONTROLLED STUDY; CROHN DISEASE; DIAGNOSTIC PROCEDURE; DISEASE ACTIVITY; DOWN REGULATION; ENTERITIS; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MATHEMATICAL ANALYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; TANDEM MASS SPECTROMETRY; ULCERATIVE COLITIS; UPREGULATION;

BIOLOGICAL MARKERS; BLOOD COAGULATION; CHROMATOGRAPHY, LIQUID; COLITIS, ULCERATIVE; COLON; CROHN DISEASE; DATABASES, PROTEIN; DIAGNOSIS, DIFFERENTIAL; DOWN-REGULATION; HUMANS; INTESTINAL MUCOSA; PROSPECTIVE STUDIES; PROTEINS; PROTEOME; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; TANDEM MASS SPECTROMETRY; UP-REGULATION;

EID: 84875604087     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/1751-2980.12035     Document Type: Article

References (25)

1. Meuwis MA, Fillet M, Geurts P etal. Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling. Biochem Pharmacol 2007; 73: 1422-1433.
2. Scaldaferri F, Correale C, Gasbarrini A, Danese S. Mucosal biomarkers in inflammatory bowel disease: key pathogenic players or disease predictors? World J Gastroenterol 2010; 16: 2616-2625.
3. Papp M, Norman GL, Altorjay I, Lakatos PL. Utility of serological markers in inflammatory bowel diseases: gadget or magic? World J Gastroenterol 2007; 13: 2028-2036.
4. Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis 2009; 41: 56-66.
5. Kim ES, Kim WH. Inflammatory bowel disease in Korea: epidemiological, genomic, clinical, and therapeutic characteristics. Gut Liver 2010; 4: 1-14.
6. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3: Article 3.
7. Brusniak MY, Bodenmiller B, Campbell D etal. Corra: Computational framework and tools for LC-MS discovery and targeted mass spectrometry-based proteomics. BMC Bioinformatics 2008; 9: 542.
8. Adams RA, Schachtrup C, Davalos D, Tsigelny I, Akassoglou K. Fibrinogen signal transduction as a mediator and therapeutic target in inflammation: lessons from multiple sclerosis. Curr Med Chem 2007; 14: 2925-2936.
9. Pan YF, Viklund IM, Tsai HH, Pettersson S, Maruyama IN. The ulcerative colitis marker protein WAFL interacts with accessory proteins in endocytosis. Int J Biol Sci 2010; 6: 163-171.
10. Kaul G, Pattan G, Rafeequi T. Eukaryotic elongation factor-2 (eEF2): its regulation and peptide chain elongation. Cell Biochem Funct 2011; 29: 227-234.
11. Danese S, Papa A, Saibeni S, Repici A, Malesci A, Vecchi M. Inflammation and coagulation in inflammatory bowel disease: the clot thickens. Am J Gastroenterol 2007; 102: 174-186.
12. Manolakis AC, Kapsoritakis AN, Tiaka EK, Potamianos SP. Calprotectin, calgranulin C, and other members of the s100 protein family in inflammatory bowel disease. Dig Dis Sci 2011; 56: 1601-1611.
13. Yamaguchi N, Isomoto H, Mukae H etal. Concentrations of α- and β-defensins in plasma of patients with inflammatory bowel disease. Inflamm Res 2009; 58: 192-197.
14. Sugi K, Saitoh O, Matsuse R etal. Antineutrophil cytoplasmic antibodies in Japanese patients with inflammatory bowel disease: prevalence and recognition of putative antigens. Am J Gastroenterol 1999; 94: 1304-1312.
15. Iaccarino L, Ghirardello A, Canova M etal. Anti-annexins autoantibodies: their role as biomarkers of autoimmune diseases. Autoimmun Rev 2011; 10: 553-558.
16. Shkoda A, Werner T, Daniel H, Gunckel M, Rogler G, Haller D. Differential protein expression profile in the intestinal epithelium from patients with inflammatory bowel disease. J Proteome Res 2007; 6: 1114-1125.
17. Saitoh O, Kojima K, Sugi K etal. Fecal eosinophil granule-derived proteins reflect disease activity in inflammatory bowel disease. Am J Gastroenterol 1999; 94: 3513-3520.
18. Nambiar PR, Gupta RR, Misra V. An 'Omics' based survey of human colon cancer. Mutat Res 2010; 693: 3-18.
19. Andoh A, Fujiyama Y, Yoshioka U etal. Elevated serum anti-carbonic anhydrase II antibodies in patients with ulcerative colitis. Int J Mol Med 2002; 9: 499-502.
20. André M, Ando S, Ballagny C etal. Intestinal fatty acid binding protein gene expression reveals the cephalocaudal patterning during zebrafish gut morphogenesis. Int J Dev Biol 2000; 44: 249-252.
21. Dooley TP, Curto EV, Reddy SP etal. Regulation of gene expression in inflammatory bowel disease and correlation with IBD drugs: screening by DNA microarrays. Inflamm Bowel Dis 2004; 10: 1-14.
22. Kobayashi K, Yagasaki M, Harada N etal. Detection of Fcy binding protein antigen in human sera and its relation with autoimmune diseases. Immunol Lett 2001; 79: 229-235.
23. Romani L, Bistoni F, Montagnoli C etal. Thymosin α1: an endogenous regulator of inflammation, immunity, and tolerance. Ann N Y Acad Sci 2007; 1112: 326-338.
24. Jones SL, Wang J, Turck CW, Brown EJ. A role for the actin-bundling protein L-plastin in the regulation of leukocyte integrin function. Proc Natl Acad Sci U S A 1998; 95: 9331-9336.
25. Hollborn M, Francke M, Iandiev I etal. Early activation of inflammation- and immune response-related genes after experimental detachment of the porcine retina. Invest Ophthalmol Vis Sci 2008; 49: 1262-1273.